About this Research Topic
Soluble epoxide hydrolase (sEH) is an enzyme that contributes importantly to metabolism of endogenous, biologically active lipids including epoxides of arachidonic acid (EETs). Soluble epoxide hydrolase inhibitors (sEHIs) were developed as a means to increase lipid epoxide-including epoxyeicosatrienoic acids (EETs) and sEHIs were found to reduce blood pressure, improve insulin sensitivity, and decrease inflammation. Further sEHI development led to initial clinical trials for hypertension and diabetes. More recently, there has been significant expansion of the potential clinical paths for sEHIs. including clinical trials for COPD, with positive initial findings demonstrating improved endothelial function in smokers with COPD.
There have also been great advances in sEHI development in the areas of CKD and neuropathic pain - with clinical trials scheduled to begin in 2019 targeting diabetic neuropathic pain.
This Research Topic seeks to capture the increasingly broad scope for the potential applications of sEHIs, covering pulmonary, kidney, diabetes, and neural pathologies. Research publications will span preclinical animal studies, early stage clinical trials, and exciting results from completed clinical trials. We would also welcome the submission of industry-based articles. In doing so, this Research Topic hopes to make a significant contribution to the exciting drug development movement for sEHIs to treat human diseases.
Keywords: Eicosanoids, Cardiovascular Disease, Diabetes, Kidney Disease, Pain, Inflammation
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.